- Home
- FEBO vs MTVA Comparison
FEBO vs MTVA Comparison
Compare FEBO & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- MTVA
- Stock Information
- Founded
- FEBO 1993
- MTVA 2014
- Country
- FEBO Hong Kong
- MTVA United States
- Employees
- FEBO N/A
- MTVA N/A
- Industry
- FEBO
- MTVA
- Sector
- FEBO
- MTVA
- Exchange
- FEBO Nasdaq
- MTVA NYSE
- Market Cap
- FEBO 12.7M
- MTVA 14.3M
- IPO Year
- FEBO 2023
- MTVA N/A
- Fundamental
- Price
- FEBO $1.09
- MTVA $0.66
- Analyst Decision
- FEBO
- MTVA Strong Buy
- Analyst Count
- FEBO 0
- MTVA 2
- Target Price
- FEBO N/A
- MTVA $7.50
- AVG Volume (30 Days)
- FEBO 5.5K
- MTVA 133.9K
- Earning Date
- FEBO 07-07-2025
- MTVA 08-13-2025
- Dividend Yield
- FEBO N/A
- MTVA N/A
- EPS Growth
- FEBO N/A
- MTVA N/A
- EPS
- FEBO N/A
- MTVA N/A
- Revenue
- FEBO $17,110,653.00
- MTVA N/A
- Revenue This Year
- FEBO N/A
- MTVA N/A
- Revenue Next Year
- FEBO N/A
- MTVA N/A
- P/E Ratio
- FEBO N/A
- MTVA N/A
- Revenue Growth
- FEBO 11.58
- MTVA N/A
- 52 Week Low
- FEBO $0.93
- MTVA $0.63
- 52 Week High
- FEBO $17.68
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- FEBO 45.42
- MTVA N/A
- Support Level
- FEBO $1.06
- MTVA N/A
- Resistance Level
- FEBO $1.15
- MTVA N/A
- Average True Range (ATR)
- FEBO 0.06
- MTVA 0.00
- MACD
- FEBO 0.00
- MTVA 0.00
- Stochastic Oscillator
- FEBO 39.47
- MTVA 0.00
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care c principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.